NCT00761215

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.

Conditions

• Skin Diseases, Infectious
• Skin Diseases, Bacterial

Interventions

Type	Name	Description
DRUG	TR-701 200 mg	oral TR-701 200 mg for 5 to 7 days
DRUG	TR-701 300 mg	oral TR-701 300 mg for 5 to 7 days
DRUG	TR-701 400 mg	TR-701 400 mg for 5 to 7 days

Timeline

• Start date: 2008-09-17
• Primary completion: 2009-02-24
• Completion: 2009-02-24
• First posted: 2008-09-29
• Last updated: 2019-11-25
• Results posted: 2014-08-07

Locations

12 sites across 1 country: United States